Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
glatiramer acetate + interferon beta-1a + interferon beta-1b
- Development stage
- Discontinued
- Lead developer
- Teva Pharmaceutical Industries
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Administration
- Subcutaneous, Intramuscular
01
Overview
This is a combination of three separate disease-modifying therapies used for the treatment of relapsing forms of multiple sclerosis (MS). Each component works through different mechanisms to reduce inflammation and slow disease progression. These medications are typically used individually rather than as a fixed combination product. Studies have shown that combining interferon beta-1a with glatiramer acetate may not provide significant benefits over monotherapy.
02
Targets
Beyond the preview
Go deeper on glatiramer acetate + interferon beta-1a + interferon beta-1b.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on glatiramer acetate + interferon beta-1a + interferon beta-1b.